Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients
Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sugara, Medha [verfasserIn] Chowdappa, Ramachandra [verfasserIn] Kumar, K. V. Veerendra [verfasserIn] Gawari, Ramesh [verfasserIn] Swamy, Shalini N. [verfasserIn] Kumar, Sandeep S. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Indian Association of Surgical Oncology 2021 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Indian Journal of Surgical Oncology - Springer-Verlag, 2010, 12(2021), 3 vom: 24. Apr., Seite 454-459 |
|---|---|
| Übergeordnetes Werk: |
volume:12 ; year:2021 ; number:3 ; day:24 ; month:04 ; pages:454-459 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13193-021-01325-5 |
|---|
| Katalog-ID: |
SPR04521638X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR04521638X | ||
| 003 | DE-627 | ||
| 005 | 20211005070223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211005s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13193-021-01325-5 |2 doi | |
| 035 | |a (DE-627)SPR04521638X | ||
| 035 | |a (SPR)s13193-021-01325-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sugara, Medha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Indian Association of Surgical Oncology 2021 | ||
| 520 | |a Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of cases. Few studies from India have examined the epigenetic profile of colorectal cancers. This study was designed to study aberrant promoter hypermethylation of two select tumour suppressor genes (p16, RASSF1a) in patients with colorectal cancer and their association with clinicopathologic features. Methods A total of 41 samples including controls were collected from colorectal cancer patients. DNA was isolated from tumour tissue, and methylation-specific PCR was performed for the 2 genes. Results p16 and RASSF1a promoter hypermethylation was found in 26% and 48% of CRC cases, respectively. RASSF1a promoter hypermethylation was more often seen in young CRC patients aged 40 years or less, and this was found to be statistically significant (p value = 0.037). Conclusion RASSF1a hypermethylation is peculiar to rectal cancers and left-sided colonic tumours in young patients. Large-scale population-based studies with extensive genetic and epigenetic characterization are required for a better understanding and further validation of our findings. For individuals diagnosed with sporadic CRC, these studies on specimen might help predict prognosis and response to therapy. | ||
| 650 | 4 | |a Colorectal cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Promoter hypermethylation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a p16/ CDKN2A |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a RASSF1a |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Chowdappa, Ramachandra |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, K. V. Veerendra |e verfasserin |4 aut | |
| 700 | 1 | |a Gawari, Ramesh |e verfasserin |4 aut | |
| 700 | 1 | |a Swamy, Shalini N. |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Sandeep S. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian Journal of Surgical Oncology |d Springer-Verlag, 2010 |g 12(2021), 3 vom: 24. Apr., Seite 454-459 |w (DE-627)SPR030797241 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:3 |g day:24 |g month:04 |g pages:454-459 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13193-021-01325-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 3 |b 24 |c 04 |h 454-459 | ||
| author_variant |
m s ms r c rc k v v k kvv kvvk r g rg s n s sn sns s s k ss ssk |
|---|---|
| matchkey_str |
sugaramedhachowdapparamachandrakumarkvve:2021----:bratrmtryemtyainf1adas1gnsnooetlacri |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.1007/s13193-021-01325-5 doi (DE-627)SPR04521638X (SPR)s13193-021-01325-5-e DE-627 ger DE-627 rakwb eng Sugara, Medha verfasserin aut Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of cases. Few studies from India have examined the epigenetic profile of colorectal cancers. This study was designed to study aberrant promoter hypermethylation of two select tumour suppressor genes (p16, RASSF1a) in patients with colorectal cancer and their association with clinicopathologic features. Methods A total of 41 samples including controls were collected from colorectal cancer patients. DNA was isolated from tumour tissue, and methylation-specific PCR was performed for the 2 genes. Results p16 and RASSF1a promoter hypermethylation was found in 26% and 48% of CRC cases, respectively. RASSF1a promoter hypermethylation was more often seen in young CRC patients aged 40 years or less, and this was found to be statistically significant (p value = 0.037). Conclusion RASSF1a hypermethylation is peculiar to rectal cancers and left-sided colonic tumours in young patients. Large-scale population-based studies with extensive genetic and epigenetic characterization are required for a better understanding and further validation of our findings. For individuals diagnosed with sporadic CRC, these studies on specimen might help predict prognosis and response to therapy. Colorectal cancer (dpeaa)DE-He213 Promoter hypermethylation (dpeaa)DE-He213 p16/ CDKN2A (dpeaa)DE-He213 RASSF1a (dpeaa)DE-He213 Chowdappa, Ramachandra verfasserin aut Kumar, K. V. Veerendra verfasserin aut Gawari, Ramesh verfasserin aut Swamy, Shalini N. verfasserin aut Kumar, Sandeep S. verfasserin aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 3 vom: 24. Apr., Seite 454-459 (DE-627)SPR030797241 nnns volume:12 year:2021 number:3 day:24 month:04 pages:454-459 https://dx.doi.org/10.1007/s13193-021-01325-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 3 24 04 454-459 |
| spelling |
10.1007/s13193-021-01325-5 doi (DE-627)SPR04521638X (SPR)s13193-021-01325-5-e DE-627 ger DE-627 rakwb eng Sugara, Medha verfasserin aut Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of cases. Few studies from India have examined the epigenetic profile of colorectal cancers. This study was designed to study aberrant promoter hypermethylation of two select tumour suppressor genes (p16, RASSF1a) in patients with colorectal cancer and their association with clinicopathologic features. Methods A total of 41 samples including controls were collected from colorectal cancer patients. DNA was isolated from tumour tissue, and methylation-specific PCR was performed for the 2 genes. Results p16 and RASSF1a promoter hypermethylation was found in 26% and 48% of CRC cases, respectively. RASSF1a promoter hypermethylation was more often seen in young CRC patients aged 40 years or less, and this was found to be statistically significant (p value = 0.037). Conclusion RASSF1a hypermethylation is peculiar to rectal cancers and left-sided colonic tumours in young patients. Large-scale population-based studies with extensive genetic and epigenetic characterization are required for a better understanding and further validation of our findings. For individuals diagnosed with sporadic CRC, these studies on specimen might help predict prognosis and response to therapy. Colorectal cancer (dpeaa)DE-He213 Promoter hypermethylation (dpeaa)DE-He213 p16/ CDKN2A (dpeaa)DE-He213 RASSF1a (dpeaa)DE-He213 Chowdappa, Ramachandra verfasserin aut Kumar, K. V. Veerendra verfasserin aut Gawari, Ramesh verfasserin aut Swamy, Shalini N. verfasserin aut Kumar, Sandeep S. verfasserin aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 3 vom: 24. Apr., Seite 454-459 (DE-627)SPR030797241 nnns volume:12 year:2021 number:3 day:24 month:04 pages:454-459 https://dx.doi.org/10.1007/s13193-021-01325-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 3 24 04 454-459 |
| allfields_unstemmed |
10.1007/s13193-021-01325-5 doi (DE-627)SPR04521638X (SPR)s13193-021-01325-5-e DE-627 ger DE-627 rakwb eng Sugara, Medha verfasserin aut Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of cases. Few studies from India have examined the epigenetic profile of colorectal cancers. This study was designed to study aberrant promoter hypermethylation of two select tumour suppressor genes (p16, RASSF1a) in patients with colorectal cancer and their association with clinicopathologic features. Methods A total of 41 samples including controls were collected from colorectal cancer patients. DNA was isolated from tumour tissue, and methylation-specific PCR was performed for the 2 genes. Results p16 and RASSF1a promoter hypermethylation was found in 26% and 48% of CRC cases, respectively. RASSF1a promoter hypermethylation was more often seen in young CRC patients aged 40 years or less, and this was found to be statistically significant (p value = 0.037). Conclusion RASSF1a hypermethylation is peculiar to rectal cancers and left-sided colonic tumours in young patients. Large-scale population-based studies with extensive genetic and epigenetic characterization are required for a better understanding and further validation of our findings. For individuals diagnosed with sporadic CRC, these studies on specimen might help predict prognosis and response to therapy. Colorectal cancer (dpeaa)DE-He213 Promoter hypermethylation (dpeaa)DE-He213 p16/ CDKN2A (dpeaa)DE-He213 RASSF1a (dpeaa)DE-He213 Chowdappa, Ramachandra verfasserin aut Kumar, K. V. Veerendra verfasserin aut Gawari, Ramesh verfasserin aut Swamy, Shalini N. verfasserin aut Kumar, Sandeep S. verfasserin aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 3 vom: 24. Apr., Seite 454-459 (DE-627)SPR030797241 nnns volume:12 year:2021 number:3 day:24 month:04 pages:454-459 https://dx.doi.org/10.1007/s13193-021-01325-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 3 24 04 454-459 |
| allfieldsGer |
10.1007/s13193-021-01325-5 doi (DE-627)SPR04521638X (SPR)s13193-021-01325-5-e DE-627 ger DE-627 rakwb eng Sugara, Medha verfasserin aut Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of cases. Few studies from India have examined the epigenetic profile of colorectal cancers. This study was designed to study aberrant promoter hypermethylation of two select tumour suppressor genes (p16, RASSF1a) in patients with colorectal cancer and their association with clinicopathologic features. Methods A total of 41 samples including controls were collected from colorectal cancer patients. DNA was isolated from tumour tissue, and methylation-specific PCR was performed for the 2 genes. Results p16 and RASSF1a promoter hypermethylation was found in 26% and 48% of CRC cases, respectively. RASSF1a promoter hypermethylation was more often seen in young CRC patients aged 40 years or less, and this was found to be statistically significant (p value = 0.037). Conclusion RASSF1a hypermethylation is peculiar to rectal cancers and left-sided colonic tumours in young patients. Large-scale population-based studies with extensive genetic and epigenetic characterization are required for a better understanding and further validation of our findings. For individuals diagnosed with sporadic CRC, these studies on specimen might help predict prognosis and response to therapy. Colorectal cancer (dpeaa)DE-He213 Promoter hypermethylation (dpeaa)DE-He213 p16/ CDKN2A (dpeaa)DE-He213 RASSF1a (dpeaa)DE-He213 Chowdappa, Ramachandra verfasserin aut Kumar, K. V. Veerendra verfasserin aut Gawari, Ramesh verfasserin aut Swamy, Shalini N. verfasserin aut Kumar, Sandeep S. verfasserin aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 3 vom: 24. Apr., Seite 454-459 (DE-627)SPR030797241 nnns volume:12 year:2021 number:3 day:24 month:04 pages:454-459 https://dx.doi.org/10.1007/s13193-021-01325-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 3 24 04 454-459 |
| allfieldsSound |
10.1007/s13193-021-01325-5 doi (DE-627)SPR04521638X (SPR)s13193-021-01325-5-e DE-627 ger DE-627 rakwb eng Sugara, Medha verfasserin aut Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of cases. Few studies from India have examined the epigenetic profile of colorectal cancers. This study was designed to study aberrant promoter hypermethylation of two select tumour suppressor genes (p16, RASSF1a) in patients with colorectal cancer and their association with clinicopathologic features. Methods A total of 41 samples including controls were collected from colorectal cancer patients. DNA was isolated from tumour tissue, and methylation-specific PCR was performed for the 2 genes. Results p16 and RASSF1a promoter hypermethylation was found in 26% and 48% of CRC cases, respectively. RASSF1a promoter hypermethylation was more often seen in young CRC patients aged 40 years or less, and this was found to be statistically significant (p value = 0.037). Conclusion RASSF1a hypermethylation is peculiar to rectal cancers and left-sided colonic tumours in young patients. Large-scale population-based studies with extensive genetic and epigenetic characterization are required for a better understanding and further validation of our findings. For individuals diagnosed with sporadic CRC, these studies on specimen might help predict prognosis and response to therapy. Colorectal cancer (dpeaa)DE-He213 Promoter hypermethylation (dpeaa)DE-He213 p16/ CDKN2A (dpeaa)DE-He213 RASSF1a (dpeaa)DE-He213 Chowdappa, Ramachandra verfasserin aut Kumar, K. V. Veerendra verfasserin aut Gawari, Ramesh verfasserin aut Swamy, Shalini N. verfasserin aut Kumar, Sandeep S. verfasserin aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 3 vom: 24. Apr., Seite 454-459 (DE-627)SPR030797241 nnns volume:12 year:2021 number:3 day:24 month:04 pages:454-459 https://dx.doi.org/10.1007/s13193-021-01325-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 3 24 04 454-459 |
| language |
English |
| source |
Enthalten in Indian Journal of Surgical Oncology 12(2021), 3 vom: 24. Apr., Seite 454-459 volume:12 year:2021 number:3 day:24 month:04 pages:454-459 |
| sourceStr |
Enthalten in Indian Journal of Surgical Oncology 12(2021), 3 vom: 24. Apr., Seite 454-459 volume:12 year:2021 number:3 day:24 month:04 pages:454-459 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Colorectal cancer Promoter hypermethylation p16/ CDKN2A RASSF1a |
| isfreeaccess_bool |
false |
| container_title |
Indian Journal of Surgical Oncology |
| authorswithroles_txt_mv |
Sugara, Medha @@aut@@ Chowdappa, Ramachandra @@aut@@ Kumar, K. V. Veerendra @@aut@@ Gawari, Ramesh @@aut@@ Swamy, Shalini N. @@aut@@ Kumar, Sandeep S. @@aut@@ |
| publishDateDaySort_date |
2021-04-24T00:00:00Z |
| hierarchy_top_id |
SPR030797241 |
| id |
SPR04521638X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR04521638X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20211005070223.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">211005s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13193-021-01325-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR04521638X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13193-021-01325-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sugara, Medha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Association of Surgical Oncology 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of cases. Few studies from India have examined the epigenetic profile of colorectal cancers. This study was designed to study aberrant promoter hypermethylation of two select tumour suppressor genes (p16, RASSF1a) in patients with colorectal cancer and their association with clinicopathologic features. Methods A total of 41 samples including controls were collected from colorectal cancer patients. DNA was isolated from tumour tissue, and methylation-specific PCR was performed for the 2 genes. Results p16 and RASSF1a promoter hypermethylation was found in 26% and 48% of CRC cases, respectively. RASSF1a promoter hypermethylation was more often seen in young CRC patients aged 40 years or less, and this was found to be statistically significant (p value = 0.037). Conclusion RASSF1a hypermethylation is peculiar to rectal cancers and left-sided colonic tumours in young patients. Large-scale population-based studies with extensive genetic and epigenetic characterization are required for a better understanding and further validation of our findings. For individuals diagnosed with sporadic CRC, these studies on specimen might help predict prognosis and response to therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Colorectal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Promoter hypermethylation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">p16/ CDKN2A</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RASSF1a</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chowdappa, Ramachandra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kumar, K. V. Veerendra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gawari, Ramesh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Swamy, Shalini N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kumar, Sandeep S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Surgical Oncology</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">12(2021), 3 vom: 24. Apr., Seite 454-459</subfield><subfield code="w">(DE-627)SPR030797241</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield><subfield code="g">day:24</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:454-459</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13193-021-01325-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield><subfield code="b">24</subfield><subfield code="c">04</subfield><subfield code="h">454-459</subfield></datafield></record></collection>
|
| author |
Sugara, Medha |
| spellingShingle |
Sugara, Medha misc Colorectal cancer misc Promoter hypermethylation misc p16/ CDKN2A misc RASSF1a Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients |
| authorStr |
Sugara, Medha |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR030797241 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients Colorectal cancer (dpeaa)DE-He213 Promoter hypermethylation (dpeaa)DE-He213 p16/ CDKN2A (dpeaa)DE-He213 RASSF1a (dpeaa)DE-He213 |
| topic |
misc Colorectal cancer misc Promoter hypermethylation misc p16/ CDKN2A misc RASSF1a |
| topic_unstemmed |
misc Colorectal cancer misc Promoter hypermethylation misc p16/ CDKN2A misc RASSF1a |
| topic_browse |
misc Colorectal cancer misc Promoter hypermethylation misc p16/ CDKN2A misc RASSF1a |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Indian Journal of Surgical Oncology |
| hierarchy_parent_id |
SPR030797241 |
| hierarchy_top_title |
Indian Journal of Surgical Oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR030797241 |
| title |
Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients |
| ctrlnum |
(DE-627)SPR04521638X (SPR)s13193-021-01325-5-e |
| title_full |
Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients |
| author_sort |
Sugara, Medha |
| journal |
Indian Journal of Surgical Oncology |
| journalStr |
Indian Journal of Surgical Oncology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
454 |
| author_browse |
Sugara, Medha Chowdappa, Ramachandra Kumar, K. V. Veerendra Gawari, Ramesh Swamy, Shalini N. Kumar, Sandeep S. |
| container_volume |
12 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sugara, Medha |
| doi_str_mv |
10.1007/s13193-021-01325-5 |
| author2-role |
verfasserin |
| title_sort |
aberrant promoter hypermethylation of p16 and rassf1a genes in colorectal cancer – significance in young patients |
| title_auth |
Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients |
| abstract |
Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of cases. Few studies from India have examined the epigenetic profile of colorectal cancers. This study was designed to study aberrant promoter hypermethylation of two select tumour suppressor genes (p16, RASSF1a) in patients with colorectal cancer and their association with clinicopathologic features. Methods A total of 41 samples including controls were collected from colorectal cancer patients. DNA was isolated from tumour tissue, and methylation-specific PCR was performed for the 2 genes. Results p16 and RASSF1a promoter hypermethylation was found in 26% and 48% of CRC cases, respectively. RASSF1a promoter hypermethylation was more often seen in young CRC patients aged 40 years or less, and this was found to be statistically significant (p value = 0.037). Conclusion RASSF1a hypermethylation is peculiar to rectal cancers and left-sided colonic tumours in young patients. Large-scale population-based studies with extensive genetic and epigenetic characterization are required for a better understanding and further validation of our findings. For individuals diagnosed with sporadic CRC, these studies on specimen might help predict prognosis and response to therapy. © Indian Association of Surgical Oncology 2021 |
| abstractGer |
Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of cases. Few studies from India have examined the epigenetic profile of colorectal cancers. This study was designed to study aberrant promoter hypermethylation of two select tumour suppressor genes (p16, RASSF1a) in patients with colorectal cancer and their association with clinicopathologic features. Methods A total of 41 samples including controls were collected from colorectal cancer patients. DNA was isolated from tumour tissue, and methylation-specific PCR was performed for the 2 genes. Results p16 and RASSF1a promoter hypermethylation was found in 26% and 48% of CRC cases, respectively. RASSF1a promoter hypermethylation was more often seen in young CRC patients aged 40 years or less, and this was found to be statistically significant (p value = 0.037). Conclusion RASSF1a hypermethylation is peculiar to rectal cancers and left-sided colonic tumours in young patients. Large-scale population-based studies with extensive genetic and epigenetic characterization are required for a better understanding and further validation of our findings. For individuals diagnosed with sporadic CRC, these studies on specimen might help predict prognosis and response to therapy. © Indian Association of Surgical Oncology 2021 |
| abstract_unstemmed |
Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of cases. Few studies from India have examined the epigenetic profile of colorectal cancers. This study was designed to study aberrant promoter hypermethylation of two select tumour suppressor genes (p16, RASSF1a) in patients with colorectal cancer and their association with clinicopathologic features. Methods A total of 41 samples including controls were collected from colorectal cancer patients. DNA was isolated from tumour tissue, and methylation-specific PCR was performed for the 2 genes. Results p16 and RASSF1a promoter hypermethylation was found in 26% and 48% of CRC cases, respectively. RASSF1a promoter hypermethylation was more often seen in young CRC patients aged 40 years or less, and this was found to be statistically significant (p value = 0.037). Conclusion RASSF1a hypermethylation is peculiar to rectal cancers and left-sided colonic tumours in young patients. Large-scale population-based studies with extensive genetic and epigenetic characterization are required for a better understanding and further validation of our findings. For individuals diagnosed with sporadic CRC, these studies on specimen might help predict prognosis and response to therapy. © Indian Association of Surgical Oncology 2021 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
3 |
| title_short |
Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients |
| url |
https://dx.doi.org/10.1007/s13193-021-01325-5 |
| remote_bool |
true |
| author2 |
Chowdappa, Ramachandra Kumar, K. V. Veerendra Gawari, Ramesh Swamy, Shalini N. Kumar, Sandeep S. |
| author2Str |
Chowdappa, Ramachandra Kumar, K. V. Veerendra Gawari, Ramesh Swamy, Shalini N. Kumar, Sandeep S. |
| ppnlink |
SPR030797241 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13193-021-01325-5 |
| up_date |
2024-07-03T14:32:06.923Z |
| _version_ |
1803568678878314496 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR04521638X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20211005070223.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">211005s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13193-021-01325-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR04521638X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13193-021-01325-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sugara, Medha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Aberrant Promoter Hypermethylation of p16 and RASSF1a Genes in Colorectal Cancer – Significance in Young Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Association of Surgical Oncology 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective The clinical profile of colorectal cancers (CRC) in India is different from that described in western countries. Microsatellite instability and APC mutation explain the molecular biology of up to 50% of colorectal cancers. Global genome hypermethylation may be the cause in at least 20% of cases. Few studies from India have examined the epigenetic profile of colorectal cancers. This study was designed to study aberrant promoter hypermethylation of two select tumour suppressor genes (p16, RASSF1a) in patients with colorectal cancer and their association with clinicopathologic features. Methods A total of 41 samples including controls were collected from colorectal cancer patients. DNA was isolated from tumour tissue, and methylation-specific PCR was performed for the 2 genes. Results p16 and RASSF1a promoter hypermethylation was found in 26% and 48% of CRC cases, respectively. RASSF1a promoter hypermethylation was more often seen in young CRC patients aged 40 years or less, and this was found to be statistically significant (p value = 0.037). Conclusion RASSF1a hypermethylation is peculiar to rectal cancers and left-sided colonic tumours in young patients. Large-scale population-based studies with extensive genetic and epigenetic characterization are required for a better understanding and further validation of our findings. For individuals diagnosed with sporadic CRC, these studies on specimen might help predict prognosis and response to therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Colorectal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Promoter hypermethylation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">p16/ CDKN2A</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RASSF1a</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chowdappa, Ramachandra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kumar, K. V. Veerendra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gawari, Ramesh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Swamy, Shalini N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kumar, Sandeep S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Surgical Oncology</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">12(2021), 3 vom: 24. Apr., Seite 454-459</subfield><subfield code="w">(DE-627)SPR030797241</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield><subfield code="g">day:24</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:454-459</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13193-021-01325-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield><subfield code="b">24</subfield><subfield code="c">04</subfield><subfield code="h">454-459</subfield></datafield></record></collection>
|
| score |
7.3987055 |